Compare Global X Autonomous & Electric Vehicles (DRIV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Inovio Pharmaceuticals Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.85, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| DRIV | INO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $2.87 |
52-Week Low | $25.23 | $0.66 |
Market Cap | — | $78.55M |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.85, up 0.79% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights global EV sales growth, with DRIV outperforming peers due to its focus on autonomous technology and software, gaining 38% year-to-date according to Seeking Alpha on 2026-05-14.
The outlook remains positive given sector tailwinds, but risks include competitive pressures from Chinese automakers and sensitivity to fuel price fluctuations. Analyst sentiment is bullish, supported by institutional interest in EV and autonomous driving exposure.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
